SBP Group (01177.HK) today announced a strategic multi-program option and license agreement with Boehringer Ingelheim to advance potential next-generation cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies. Building on the companies’ existing collaboration in oncology, the agreement will bring together SBP Group’s innovative platforms and early-development capabilities with Boehringer Ingelheim’s global oncology expertise to advance new treatment approaches for patients worldwide.

From October 23 to 27 (local time), the 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. Studies on 2 investigational products and 3 marketed products from Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), were selected for presentation.

On October 23 (local time), at the 2026 European Society for Medical Oncology (ESMO) Congress, TQB2102, a new-generation HER2 bispecific antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), released the results of a Phase II clinical study evaluating TQB2102 in combination with benmelstobart (TQB2450) ± capecitabine as first-line treatment for HER2-positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC).

On October 23 (local time), at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, TQB2102, a new-generation HER2 bispecific antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), announced the latest data from the pivotal Phase III clinical study (APEX-Breast01) for the treatment of HER2-low advanced breast cancer.